Novo Nordisk’s injectable GLP-1RA sales may increase upon imminent label expansion, says GlobalData – Pharma News
Novo Nordisk recently announced that its FLOW trial, which studies Ozempic (semaglutide) in diabetic patients with chronic kidney disease (CKD), will come to a halt almost one year prior to the planned completion date, as interim results alone were sufficient in proving that the treatment was successful in treating kidney failure in this patient group. … Read more